UTv Videos

Although BCG has been the standard of care for decades and remains the most effective available treatment, outcomes remain suboptimal for many patients.

Lina Posada Calderon, MD, discusses the background and key takeaways from her team’s study examining germline BAP1-associated renal cell carcinoma.

Alam frames PHI and MRI as noninvasive tools that help refine risk before proceeding to biopsy.

Despite improvements, Kalyani Narra, MD, highlights persistent gaps in referral among eligible patients.

John P. Sfakianos, MD, outlines the scientific rationale for combining systemic immunotherapy with BCG in the BCG-naïve NMIBC setting.

Wesley Hauwei Chou, MD, outlined 2 projects evaluating potential biomarkers for treatment response in renal cell carcinoma.

When symptoms appear tied to the menstrual cycle, pharmacologic options can be used as short-term support.

Iman Sadri, MD, CM, discusses a somatic-autonomic nerve grafting technique for patients with persistent erectile dysfunction after radical prostatectomy.

The session emphasized how rapidly evolving AI technologies are addressing long-standing inefficiencies in urologic care.

Aleece Fosnight, MSPAS, PA-C, highlights pattern recognition as a cornerstone of diagnosis, encouraging clinicians to closely examine how urinary symptoms fluctuate across the menstrual cycle.

A key finding was that among the qualities applicants highlighted, only “learning and growth” correlated with interview selection.

Maxwell L. Sandberg, MD, highlights a study on survival outcomes between patients who underwent CN-TT via an open, laparoscopic, or robotic approach.

Notable findings highlighted stark differences between this safety-net population and national averages.

Fed Ghali, MD, discusses the phase 2 CONSOLIdaTE-01 trial, assessing the role for consolidative local therapy following disease control on EV/P.

Jennifer Miles-Thomas, MD, URPS, MBA, emphasizes that teleurology and team-based care models offer significant promise

Mark D. Tyson, II, MD, MPH, highlights interim findings from the ADVANCED-2 trial of TARA-002 in BCG-naïve NMIBC.

The study retrospectively analyzed 456 biopsy-naive men who underwent PHI testing followed by a prostate biopsy.

In the final installment in a 5-part series, Richard Wassersug, PhD, and Paul F. Schellhammer, MD, FACS, discuss strategies for establishing transdermal estradiol as a recognized therapy for men undergoing androgen deprivation therapy for prostate cancer.

In part 4 of a 5-part series, Richard Wassersug, PhD, and Paul F. Schellhammer, MD, FACS, focus on concerns about the adverse events of transdermal estradiol, particularly gynecomastia.

In part 3 of a 5-part series, Richard Wassersug, PhD, and Paul F. Schellhammer, MD, FACS, discuss emerging evidence supporting transdermal estradiol as an effective and potentially superior alternative to traditional LHRH analogue ADT for advanced prostate cancer.

In part 2 of a 5-part series, Richard Wassersug, PhD, and Paul F. Schellhammer, MD, FACS, explore the historical, clinical, and systemic barriers to using transdermal estradiol as a treatment for prostate cancer, while highlighting its potential benefits.

In this opening segment, Richard Wassersug, PhD, and Paul F. Schellhammer, MD, FACS, discuss the origins, goals, and challenges of the Estradiol Initiative.

Harras Zaid, MD, discusses the complex decision-making involved in managing renal tumors with associated tumor thrombus.

Tom Jayram, MD, discusses the phase 2 SURF302 trial of TYRA-300, a FGFR3-selective inhibitor for FGFR3-altered LG-IR-NMIBC.

Fed Ghali, MD, highlights simulated outcomes of the EV-302 trial when adjusting for use of maintenance avelumab in the control arm.

One of the most notable changes is a new thematic structure within urologic oncology.

The study assessed descriptive sequencing and oncologic outcomes among patients receiving gene therapy for BCG-unresponsive NMIBC.

Jim C. Hu, MD, MPH, discusses the functional advantages of a posterior approach to endopelvic neurovascular total sparing (PATENTS) robotic-assisted radical prostatectomy.